Avalo Therapeutics Email Format
Biotechnology ResearchPennsylvania, United States11-50 Employees
Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation, with its lead asset, AVTX-009, targeting inflammatory diseases through an anti-IL-1β mechanism. The company emphasizes a targeted approach aimed at accelerating development and increasing the likelihood of clinical success, pursuing a pipeline that spans immunology, immuno-oncology, and rare genetic diseases, with particular emphasis on rare pediatric and orphan conditions. Based in Chesterbrook, Pennsylvania, Avalo operates within the biotechnology research sector and is advancing therapies aimed at areas with high unmet medical need in immune-mediated inflammatory diseases. The organization is developing its program through the clinical trial process, including ongoing efforts in hidradenitis suppurativa as part of its broader IL-1β-focused strategy. Recent leadership and governance changes reflect ongoing expansion of its executive and board expertise as the company progresses its clinical plans.
1-888-653-2347 
support@leadiq.com 
